Cardiovascular Drugs
1,021 FDA-approved drugs
TheraRadar tracks 1,021 FDA-approved cardiovascular drugs from 291 companies across 54 drug classes, led by B BRAUN, with 1,570 active clinical trials in the pipeline. Explore recent approvals, top companies, active trials by indication, and drug classes for Cardiovascular.
Cardiovascular Approvals by Year
14
'15
17
'16
14
'17
7
'18
15
'19
12
'20
18
'21
17
'22
9
'23
14
'24
19
'25
1
'26
Recent Cardiovascular Drug Approvals
SUNHARBO
ASUNDEXIAN
Secondary stroke prevention...
2026-11-09
Bayer
Factor XIa
MYQORZO
AFICAMTEN
adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacit...
2025-12-19
CYTOKINETICS
Cardiac Myosin
CARDAMYST
ETRIPAMIL
the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to si...
2025-12-12
MILESTONE PHARMS USA
L-type calcium channel
JAVADIN
CLONIDINE HYDROCHLORIDE
hypertension in adult patients, to lower blood pressure...
2025-10-23
AZURITY
alpha-adrenoreceptors
LASIX ONYU
FUROSEMIDE
edema in adult patients with chronic heart failure...
2025-10-07
SQ INNOVATION
ENBUMYST
BUMETANIDE
edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic s...
2025-09-12
CORSTASIS THERAP
CANGRELOR
CANGRELOR
Cangrelor for injection is indicated as an adjunct to percutaneous coronary intervention (PCI) to re...
2025-08-11
MSN
P2Y12
SDAMLO
AMLODIPINE BESYLATE
hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older...
2025-07-24
BRILLIAN PHARMA
Calcium channel
VOSTALLY
RAMIPRIL
hypertension, to lower blood pressure...
2025-07-23
ROSEMONT PHARMS
ACE
DEHYDRATED ALCOHOL
DEHYDRATED ALCOHOL
1 INDICATIONS & USAGE Dehydrated alcohol injection is indicated to induce controlled cardiac septal ...
2025-06-23
BE PHARMS
WIDAPLIK
AMLODIPINE BESYLATE
hypertension in adult patients, to lower blood pressure...
2025-06-05
AZURITY
ANGIOTENSIN ll ACETATE
ANGIOTENSIN II ACETATE
2025-06-03
GLAND
YUTREPIA
TREPROSTINIL SODIUM
pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability...
2025-05-23
LIQUIDIA TECH
ELIQUIS SPRINKLE
APIXABAN
2025-04-17
Bristol-Myers Squibb
Factor Xa
HEMICLOR
CHLORTHALIDONE
hypertension in adults, to lower blood pressure...
2025-03-17
PRM PHARMA
ARBLI
LOSARTAN POTASSIUM
hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure...
2025-03-13
SCIENTURE
AT1 receptor
RIVAROXABAN
RIVAROXABAN
Rivaroxaban tablet is a factor Xa inhibitor indicated: to reduce the risk of major cardiovascular ev...
2025-03-03
MACLEODS PHARMS
Factor Xa
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE
DILTIAZEM HYDROCHLORIDE
the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutte...
2025-02-21
HQ SPCLT PHARMA
INZIRQO
HYDROCHLOROTHIAZIDE
hypertension in adult and pediatric patients, to lower blood pressure...
2025-01-28
NOVITIUM PHARMA
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE
AZILSARTAN KAMEDOXOMIL
hypertension, to lower blood pressure...
2025-01-21
ALKEM LABS LTD
AT1 receptor
Showing the 20 most recent of 1,021 cardiovascular drugs. View all 1,021 →
Top Cardiovascular Companies
Cardiovascular Active Trials by Indication
1,570 active trials — the forward pipeline, not just approvals.
Stroke 397 Hypertension 347 Heart Failure 288 Coronary Artery Disease 183 Atrial Fibrillation 138 Myocardial Infarction 105 Thrombosis 59 Hypertrophic Cardiomyopathy 27
All competitive landscapes → Cardiovascular Drug Classes
Thiazide Diuretic 27
Angiotensin 2 Receptor Blocker 12
Nitrate Vasodilator 9
Loop Diuretic 8
Thiazide-like Diuretic 8
Dihydropyridine Calcium Channel Blocker 7
Endothelin Receptor Antagonist 6
Central alpha-2 Adrenergic Agonist 6
Anti-coagulant 5
Prostacycline Vasodilator 5
Cardiovascular at a Glance
- Total Drugs
- 1021
- Companies
- 291
- Drug Classes
- 54
- Active Trials
- 1,570
- Latest Approval
- 2026-11-09